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ABSTRACT
In the United States, the Food and Drug Administration (FDA) agency is responsible for regulating
the safety and efficacy of biopharmaceutical drug products. Furthermore, the FDA is tasked with
speeding new medical innovations to market. These two missions create an inherent tension within
the  agency  and  between  the  agency  and  key  stakeholders.  Oftentimes,  communications  and
interactions between regulated companies and the FDA suffer.
The focus of this research is on the interactions between the FDA and the biopharmaceutical
companies that perform drug R&D. To assess the current issues and state of communication and
interaction between the FDA and industry, we carried out a survey of industry leadership in R&D
and regulatory positions as well as senior leadership at the FDA who have responsibility for drug
evaluation and oversight.
Based on forty-nine industry and eight FDA interviews we conducted, we found that industry seeks
additional  structured  and  informal  interactions  with  the  FDA,  especially  during  Phase  II  of
development. Overall, industry placed greater value on additional communication than did the FDA.
Furthermore, industry interviewees indicated that they were willing to pay PDUFA-like fees during
clinical development to ensure that the FDA could hire additional, well-qualified staff to assist with
protocol reviews and decision-making.
Based on our survey and discussions, we uncovered several thematic opportunities to improve
interactions between the FDA and industry and to reduce clinical development times: 1) develop
metrics and goals at the FDA for clinical development times in exchange for PDUFA like fees; 2)
establish an oversight board consisting of industry, agency officials, and premier external scientists
(possibly at NIH or CDC) to evaluate and audit retrospectively completed and terminated drug
projects; and 3) construct a knowledge database that can simultaneously protect proprietary data
while  allowing  sponsor  companies  to  understand  safety  issues  and  problems  of  previously
developed/failed drug programs.
While profound scientific and medical challenges face the FDA and industry, the first step to
reducing development times and associated costs and facilitating innovation is to provide an efficient
regulatory process that reduces unnecessary uncertainty and delays due to lack of communication
and interaction.
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“The FDA is responsible for protecting the public health by assuring the safety, efficacy and 
security of human and veterinary drugs, biological products, medical devices…and…for 
advancing the public health by helping to speed innovations that make medicines and foods more 
effective, safer and more affordable…” 
 







“If biomedical science is to deliver on its promise, scientific creativity and effort must also be 
focused on improving the medical product development process itself, with the explicit goal of 
robust development pathways that are efficient and predictable and result in products that are 
safe, effective and available to patients.  We must modernize the critical development path that 
leads from scientific discovery to the patient.” 
 
     From Challenge and Opportunity on the Critical Path to New Medical Products, 
U.S. Department of Health and Human Services, Food and Drug Administration,  






“Communication leads to increased collaboration, and increased collaboration leads to successful 
drug development.” 
 






FDA Commissioner Mark McClellan believes “…that poor communication between the FDA 
and firms seeking drug approval adds months to reviews – and costs companies millions of 
dollars.” 
 
    From Daniel Kadlec, “Will This Experiment Work?”, Time, 7 July 2003. 
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I.  INTRODUCTION AND BACKGROUND 
Major scientific breakthroughs, new discovery technologies, and significant increases in 
life science R&D spending in both the private sector and at the National Institutes of Health have 
helped create prospects for the impending discovery and development of significant new 
medicines to treat unmet health needs.   Despite these scientific advances and enhanced R&D 
efforts, the number of average annual New Drug Applications (“NDAs”) and new Biologic 
License Applications (“BLAs”) approved by the US Food and Drug Administration has been 
smaller after 2000 than in the mid-1990s.
 3  Moreover, recent estimates suggest the average costs 
of bringing a new medicine to market have increased sharply to between $800 million and $1.7 
billion, with the lower estimate being two and a half times higher than similar inflation-adjusted 
estimates published a dozen years earlier.
4   
This increase in costs of bringing new medicines to market may be somewhat surprising 
since, spurred by Congressional legislation, over the last decade review times at the FDA have 
actually been declining.  Specifically, available evidence suggests that the passage and 
implementation of the Prescription Drug User Fee Act in 1992, and its successors in 1997 and 
2002, have resulted in industry and the FDA working together to reduce mean and median 
NDA/BLA approval review times substantially, by more than 40% across a wide range of 
therapeutic classes.
5    
  While the shortening of approval review times at the FDA has resulted in new drugs 
coming on to the U.S. market more rapidly, other things equal, this FDA review time comprises 
only a small proportion – about 10% to 15% -- of the total time required to discover, develop and 
market a new medical product.   MIT-FDA-Industry White Paper    5 
   
  The total time in drug development is typically broken down into pre-clinical and clinical 
stages.  Prior to a sponsor filing an Investigational New Drug (“IND”) application with the FDA, 
authorizing clinical testing of a new compound for safety in healthy humans, sponsors typically 
engage in a pre-clinical drug discovery process that lasts from one to five years.  Notably, the 
time between the IND authorization and the filing of the NDA/BLA is much more lengthy and, 
unlike the NDA/BLA review process, this interval has become longer rather than shorter.  For 
example, one recent study reports that over the eight-year period 1994-2002, the average time 
elapsed between the IND and NDA/BLA filing was 76.7 months (about 6.4 years), virtually the 
same as the 77.3 month mean over the previous eight-year period from 1986-1994.  In 
comparison, these more recent means are about a third larger than the 57.8 month (4.8 years) 
mean time interval between IND to NDA/BLA filing during the 1978-1986 time period, and 
more than 50% greater than that between 1970 and 1978.  (49.2 months, or 4.1 years).
6   
What are the underlying factors leading to increased development times and costs?  Why 
have the opportunities created by significant scientific and computational advances not yet 
resulted in greater numbers of successful and less costly new therapies being approved?  How 
can industry and the FDA adapt or transform themselves to help make the drug development 
process – both pre-clinical and clinical -- more productive?   
Given that drug development times are much longer than approval review times, and that 
the former have been increasing rather than falling in recent decades, it is clear that the drug 
development process merits a close examination.  That is the focus of the research reported here, 
which is based on results from a 2004 survey of 57 senior R&D and regulatory personnel in 
industry and at the FDA.   MIT-FDA-Industry White Paper    6 
   
  The research reported here complements a recent FDA initiative.  Specifically, in its 
March 2004 “Critical Path” document, Innovation or Stagnation: Challenge and Opportunity on 
the Critical Path to New Medical Products, the FDA considers a broad range of underlying 
scientific and manufacturing as well as clinical development issues for all types of medical 
products – pharmaceuticals, biologics, devices, diagnostics, etc.  By comparison, here we focus 
our attention on clinical development efforts involving only pharmaceuticals and biologics 
(together called “drugs”).       
  In particular, we report here the results of a recently completed confidential interview 
survey project assessing the nature of communications between the FDA and industry during the 
drug development process, and identifying opportunities to improve the management of this 
process.  The survey results were compiled after conducting interviews with 49 senior 
R&D/regulatory affairs officials at seven biotech/biopharmaceutical firms, seven pharmaceutical 
companies, and three contract research organizations (“CROs”).  To obtain comparable 
perspectives from the FDA, we also conducted analogous interviews with eight senior FDA 
officials.   
  Two features of this survey deserve special note.  First, the industry officials we 
interviewed were senior R&D and regulatory personnel, and in particular were not in the 
financial, marketing or public affairs divisions of these organizations; the views of these R&D 
and regulatory personnel may differ considerably from managers elsewhere in these company.  
Second, all survey interviews were carried out between January 8, 2004 and May 27, 2004, at 
least five months prior to the September 30, 2004 voluntary withdrawal by Merck & Co. of the 
Cox-2 inhibitor Vioxx, and the subsequent set of events involving FDA oversight of other pain 
killers, as well as hearings on the pediatric safety of antidepressant medications.      MIT-FDA-Industry White Paper    7 
   
  The outline of this paper is as follows.  In Section II we provide a brief summary of the 
clinical drug development process, and focus on significant milestones and FDA-industry 
interactions during this process.  In Section III we describe our research methods, while in 
Section IV we discuss ten sets of survey findings.   We comment on related qualitative and 
“thinking outside the box” de novo responses further in Section V, summarize themes in FDA 
and industry interviewees’ recommendations in Section VI, and note study limitations in Section 
VII.   A more detailed quantitative analysis of our findings, along with a set of appendixes 
providing further details concerning study design and research methods, are contained in a 
preliminary draft version of this paper, available upon request from the authors.
7   
II.  BRIEF OVERVIEW OF THE DRUG DEVELOPMENT PROCESS 
 
  The process of basic discovery through new drug approval consists of pre-clinical and 
clinical development.  Its structure, along with typical timelines and a recent estimate of 
conditional transition and cumulative attrition rates, is summarized in Figure 1.
8   The pre-
clinical portion of development begins with basic discovery and research and extends through   
animal testing.  Early portions of pre-clinical development consist of scientific in vitro and in 
vivo experiments and validation of principles and concepts; such research takes place within 
academic, government and industry laboratories.  Generally a lead or candidate compound is first 
identified and isolated after screening thousands of chemicals/proteins against a specific 
biological target.  Next safety/toxicity animal studies are conducted with this compound.  After 
carrying out extensive pharmacokinetic and pharmacodynamic testing in various animal models, 
the developing company, known as the sponsor, can file an Investigational New Drug (“IND”) 
application, which must clear the FDA before human testing can commence in the U.S.   The MIT-FDA-Industry White Paper    8 
   
length of this pre-clinical development process is highly variable, but it typically lasts between 
one and five years.
9 
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  Once an IND application clears the FDA, a sponsor can initiate clinical studies in 
humans.  Approximately 40% of INDs transition to Phase I trials.
10  Phase I clinical trials are 
designed primarily to test for safety and tolerability of the drug in humans through the generation 
of pharmacokinetic data involving the absorption, distribution, metabolism and excretion of the 
drug.  This phase usually involves a small group of healthy, nominally paid volunteers, 
numbering from 20 to 100 individuals, and lasts between one and three months.  Approximately 
75% of compounds transition from Phase I into Phase II.       
  In Phase II, the preliminary effectiveness of the candidate drug is assessed, as is safety 
and tolerability via continued monitoring within dose ranges established in the Phase I studies.  
Phase II trials often involve several hundred unpaid volunteers diagnosed with a particular MIT-FDA-Industry White Paper    9 
   
illness/condition, and typically take from six months to two years to complete.    Slightly less 
than 50% of NMEs tested in Phase II proceed into Phase III. 
  Phase III trials, often called pivotal clinical trials, are designed to evaluate statistically the 
safety and efficacy of the drug compared to placebo or standard of care within a larger and 
typically more diverse population.  These trials involve hundreds to several thousand patients 
(depending in part on the therapeutic area, and whether the drug treats an acute or chronic 
condition), and often include examination of alternative formulations and doses of the drug.  Due 
to these characteristics, the Phase III trials are the most costly stage of drug development.   In 
most cases the sponsor conducts several Phase III trials, with the average length of time of the 
entire Phase III process being about four years.  It is estimated that about 64% of drugs tested in 
Phase III trials transition successfully into NDAs or BLAs.
11    
  Once submitted to the FDA for review, approximately 90% of NDAs/BLAs eventually 
receive FDA approval and are marketed.  Review times now average about one year.   When the 
various between-phase and final approval transition probabilities are multiplied to achieve a 
cumulative probability, the chance of a leading drug candidate successfully proceeding from pre-
clinical to approval is about 8%; for every 12-13 compounds that were serious candidates in pre-
clinical research, only one drug will make it to market. 
  Phase IV trials, also known as post-marketing studies, are in some cases performed as a 
condition required by the FDA for initial market approval.  In other cases they are undertaken to 
obtain approval for a new indication, or are carried out for marketing purposes.  Phase IV studies 
are designed to observe the (sometimes long-term) effects of a drug in a larger and more 
heterogeneous population than studied in the Phase III trials.  It is not unusual for Phase IV 
studies to involve thousands of patients; on average, these studies take three to four years, though MIT-FDA-Industry White Paper    10 
   
for some chronic conditions, they can last much longer.  Once on the market, new patent-
protected drugs typically have 11 to 13 years of market exclusivity before facing generic 
competition, although they likely face therapeutic competition much earlier. 
  Because of the long development process (about 7.5 years on average from IND filing to 
final NDA/BLA approval), a substantial portion of drug development costs involves the 
opportunity cost of capital, i.e., earnings the sponsor could have realized had it instead invested 
funds elsewhere.   For example, in the DiMasi, Hansen and Grabowski [2003] study cited earlier, 
of the $802 million average cost of bringing a drug to market, almost exactly half ($403 million) 
consisted of direct out-of-pocket costs, while the remainder reflected opportunity costs, 
capitalized at an 11% annual real discount rate.  One recent study has reported that if the 
probability of successfully transitioning from Phase I to market approval improved by a factor of 
one-half (from 21.5% to 33%), capitalized costs per drug would be reduced by about 30% (from 
$802 to $560 MM, or $242MM).  In comparison, a reduction of 50% in out-of-pocket costs 
across all clinical development phases would have virtually the same effect, reducing capitalized 
costs by $235MM.
12  Simply stated, time is money, and the longer the development time for 
drugs, the greater the capital that is invested cumulatively.   Efforts that result in reduced pre-
clinical and clinical development times are therefore likely to be particularly valuable.  
  To understand the management issues encountered in the course of drug development, it 
is useful to depict industry-FDA interactions along the pathway involving various pre-clinical 
and clinical phases of the drug development process.  Figure 2, taken from the FDA’s March 
2004 paper, Innovation or Stagnation?  Challenge and Opportunity on the Critical Path to New 
Medical Products, provides one characterization of the most common industry-FDA interactions.  
Sponsors often meet with the agency before submitting an IND to discuss early development MIT-FDA-Industry White Paper    11 
   
plans.  During the clinical phases, there are ongoing submissions of new protocols, and 
discussions of preliminary results from testing.  Among the multiple informal and formal 
interactions between the sponsor and the FDA, there are three critical meetings.  One of the key 
meetings is called the end of Phase II-A meeting, during which preliminary findings involving 
dose and safety are discussed, as well as future clinical protocols and endpoints.  Another key  
 
   FIGURE 2:  INDUSTRY-FDA INTERACTIONS DURING DRUG DEVELOPMENT 
 
meeting is the end of Phase II meeting (“Phase II-B”), in which detailed plans are discussed for 
the design of the pivotal clinical trials, and agreement is sought on methods and endpoints 
proposed for the evaluation of safety and efficacy.  A third key meeting is the pre-BLA/NDA 
submission meeting, in which sponsors meet with medical reviewers and other FDA officials to 
discuss the clinical package about to be filed.    
III.  RESEARCH METHODS 
  A series of 49 interviews each involving at least two of the three coauthors was 
undertaken with a total of 17 drug developing companies that had locations in the United States.  MIT-FDA-Industry White Paper    12 
   
These interviews, conducted between January 8, 2004 and April 29, 2004, involved seven 
medium to large biotechnology/biopharmaceutical firms, seven very large pharmaceutical 
companies, and three contract research organizations (one of them privately held).  All of the 
pharmaceutical and biotechnology/biopharmaceutical firms are public companies, and all but one 
has at least one product on the market.   The total market capitalization of the 17 public 
companies as of April 2004 was more than a trillion dollars.  Interviews with a total of eight 
senior FDA officials were conducted by at least two of the three coauthors on May 4, 2004 and 
May 27, 2004.  
  For the industry interviews, an attempt was made to identify individuals at senior level 
positions within their company and who had significant responsibilities for pre-clinical 
development, clinical development, regulatory oversight, or combinations of these activities.  Of 
the 49 individuals interviewed, 88% held positions of Vice-President, Executive Vice-President, 
or Global Head of R&D or Regulatory Affairs.  Twenty-two individuals were interviewed from 
pharmaceutical companies, twenty-one from biotech/biopharmaceutical companies, and six from 
CROs.  For the FDA, interviews were conducted with eight individuals, each currently a division 
head or higher, and all having experiences across multiple FDA offices or divisions.    
  Both industry and FDA interviews involved quantitative and qualitative aspects.  The 
initial portion of each interview involved asking the interviewee to rank responses to a series of 
statements or questions on a scale of one to five.  Respondents identified the issues to which they 
wished to return, to discuss them in greater depth.  In the qualitative portion of the interview, the 
interviewee was encouraged to elaborate on the earlier quantitative responses of particular 
interest.   Industry interviews typically lasted 60-90 minutes, while those at the FDA were all 
approximately 60 minutes long. MIT-FDA-Industry White Paper    13 
   
 
IV.    RESULTS FROM THE SURVEY 
  We now summarize the ten most common and striking findings from our survey, 
primarily in a qualitative fashion; a more detailed and quantitative discussion is found 
elsewhere.
13 
  A.  INDUSTRY HAS GUARDED RESPECT FOR THE FDA  
  At the beginning of each company interview, we asked interviewees to rate the agency’s 
ability to regulate drug development and appropriately weigh the risks and benefits of new drugs.  
Industry gave the FDA an average rating of “good”, a rating that did not vary significantly across 
biotech, pharmaceutical and CRO respondents.  Qualitative comments from interviewees 
indicated a great deal of respect for the FDA as a whole and recognition of the challenging role 
the agency plays in evaluating new drugs.   
  Although industry’s average rating of the FDA’s effectiveness at keeping unsafe drugs 
from the market was even higher (between “good” and “excellent”), follow-on questioning 
resulted in many respondents qualifying their answers to this question with the comment that the 
agency was partly responsible for delaying the progress of some very valuable new therapies to 
market, in some cases being overly vigilant.  One global head of R&D stated the agency tended 
inappropriately to weigh drug development as a “risk-benefit” analysis.  Instead, the individual 
argued, a “risk-risk” analysis would often be more appropriate, since the tradeoff frequently 
involves comparing the risks of approving a drug having certain safety issues with the risks that 
patients face without having the therapeutic available as a treatment option.  This individual also 
stated that often it is the risk of the drug being used in inappropriate populations or combination 
therapies that causes safety concerns and delays at the FDA. MIT-FDA-Industry White Paper    14 
   
 
  B.  PDUFA HAS HAD A SIGNIFICANT BENEFICIAL IMPACT ON APPROVAL 
TIMES, BUT OTHER TRENDS ARE WORRISOME TO INDUSTRY 
  Industry interviewees agreed for the most part that the FDA had made significant efforts 
to reduce drug approval times, but that the amount and impact of efforts by the FDA to reduce 
clinical development times were modest at best.  Responses from the FDA interviewees were 
qualitatively similar to those from industry.  
  FDA interviewees acknowledged that in terms of affecting review approval times, 
PDUFA had brought about a huge cultural shift at the FDA.   As one FDA official put it, “The 
review process is now a Swiss train, not an Italian train.”  However, a number of agency officials 
also acknowledged that the focus on reducing clinical development times was still not 
universally shared, particularly among reviewing staff.    For example, one senior official noted 
that for decades facilitating reductions in clinical development times had not been perceived as a 
priority at the FDA, nor perhaps even a role the FDA ought to play.   Instead, the traditional 
attitude of reviewers has been one of asking for whatever data is necessary, without much 
concern to time delays and costs imposed on the sponsor.  Attention to the second mission of the 
FDA – promoting the public health by helping to speed access to new medical innovations – was 
a relatively recent phenomenon and less universally shared, said another official.  On the other 
hand, both FDA and industry personnel noted that the FDA’s recent record on issuing guidance 
documents was improving, and that these documents (as well as meetings leading up to them) 
helped reduce uncertainties in the drug development process.   Several interviewees specifically 
identified a recent FDA guidance document involving pediatric clinical investigations as being 
exemplary. MIT-FDA-Industry White Paper    15 
   
    When asked whether the European Medicines Evaluation Agency (“EMEA”) was more 
efficient than the FDA in approving drugs, about two-thirds of industry interviewees either 
disagreed or were neutral.   One “best practice” of the EMEA cited by several interviewees was 
its convening of an expert meeting of regulators, sponsors and academics whenever significant 
developments in a therapeutic area or treatment modality had taken place.   
    A number of industry interviewees commented that historically, a strength of the FDA 
has been that its mandate has been limited to evaluating medicines on the basis of scientific 
criteria, and not on the basis of commercial or reimbursement considerations.   Companies’ 
experiences with the EMEA and national health authorities have historically been less 
satisfactory.  Specifically, in Europe both reimbursement and approval decisions were often 
more deeply intertwined.   Others believed that the EMEA’s stand on wanting comparative trials 
(not just placebo controls) was unfortunate, for that implicitly introduced cost and price 
concerns, rather than a focus on scientific issues involving efficacy.  Several interviewees voiced 
concerns that with passage of the Medicare Drug Benefit legislation and increased collaboration 
between the FDA and the Centers for Medicare and Medicaid Services, this separation of 
mandates could become more blurred in the U.S. as well. 
  C.  EXCESSIVE VARIABILITY ACROSS DIVISIONS AT THE FDA 
    In almost every company interview, respondents indicated that there was a high degree of 
variability in competence, communications and implementation of rules and regulations across 
divisions at the FDA.  A substantial number of respondents characterized the FDA as being 
organized like a “cottage industry”, where divisions are relatively independent, interacting in 
highly variable ways with sponsors.   MIT-FDA-Industry White Paper    16 
   
  While acknowledging that various divisions in the Center for Drug Evaluation and 
Research (“CDER”) are engaged in different therapeutic areas and thus would reasonably be 
expected to have different requirements for establishing safety and efficacy, company 
interviewees repeatedly stated that the ways and extent to which divisions interact and respond to 
sponsors is highly variable, from simple matters such as returning phone calls to more complex 
issues such as feedback on clinical protocols and NDAs/BLAs.   
   Several divisions were consistently identified by industry as having “best practices” that 
accelerated the drug development process and made it more predictable.  These best practices 
included the following:   
·  rapid turnaround of agreement on meeting minutes (in some cases before the end of 
the meeting, projected onto a screen visible by all); 
·  invitation by the FDA to the sponsor to make a half-day presentation to the 
therapeutic division on a novel drug, including a discussion of the underlying science 
and outcome metrics; and  
·  implementation of an open communication policy, including FDA commitment of 
within 24-hour acknowledgement of sponsor phone call.   
  However, several other divisions were identified by interviewees as having “worst 
practices”.  Such practices included:  
·  very poor communication protocols (only willing to discuss issues via letters, and not 
the telephone);  
·  extended time delay in resolving issues relative to FDA-sponsor commitments, 
including multiple changes in previously agreed upon decisions between the sponsor 
and the FDA;  MIT-FDA-Industry White Paper    17 
   
·  ambiguous advice and unwillingness to commit to protocols; and  
·  preoccupation with minor statistical issues essentially unrelated to therapy evaluation, 
e.g., a patient’s bowel surgery while on an antidepressant. 
  Agency officials are very much aware of variability in communications protocols across 
divisions.  When asked how sponsor companies would rate the consistency of communications 
and interactions across therapeutic divisions, FDA interviewees rated these as on average being 
slightly above poor.  One senior agency official stated that an outside consultant had recently 
been retained to address how best practices could be defined across the FDA’s divisions, and 
what metrics could be put in place to monitor progress.    In an initial attempt to address these 
issues explicitly, in October 2003 the FDA issued a draft guidance document on Good Review 
Management Principles, designed for both industry and FDA staff.  At the time of our interviews 
in May 2004, apparently this document was in the process of being revised.  As an aside, this 
individual also noted some disagreement with the above-named best practice of the FDA and 
industry agreeing on minutes at the end of meetings, and perhaps even projecting them on a 
screen for all to see.  One potential problem with that, this individual argued, was that the 
minutes might be unable adequately to explain why a particular decision had been made.  The 
underlying rationale was often important, and if not memorialized in minutes, with fading 
memories its absence could complicate downstream negotiations and decision-making, as well as 
obfuscate applicability to other development projects.    
  Biotech companies in particular expressed concern over the merger of CBER and CDER, 
noting that CBER had established a track record of engaging in many of the best practices (quick 
response to sponsor inquiries, accessibility of reviewers and leadership, proactive interest in the MIT-FDA-Industry White Paper    18 
   
underlying science) which they feared might not be sustained under the auspices of an 
augmented CDER. 
  D.  MIXED VIEWS ON APPROPRIATE TRAINING OF MEDICAL REVIEWERS
  Industry respondents rated the training of medical reviewers after joining the agency (not 
their previous education or training) as generally being “fair” to “poor”.  Follow-on questions 
revealed that in fact industry has relatively little knowledge of the on-the-job and other formal 
training FDA medical reviewers receive, although several interviewees indicated they had made 
presentations at an “FDA campus”.  Numerous company interviewees acknowledged that the 
FDA medical reviewers have a very difficult job, that many work long hours and likely are 
underpaid relative to industry employees.    
  In comparison, FDA respondents rated the ongoing training of their medical reviewers 
much higher, being on average “good”.  However, follow-on discussion with FDA officials 
revealed that while the scientific training of reviewers was generally of high quality, in most 
cases they had little if any management training.   One FDA official noted wryly that since so 
many of the reviewers were trained as physicians and/or academics, it should not be surprising 
that their “people skill” and “management skill” sets may be lacking, and that industry might 
understandably assess them as being of low quality on these dimensions.   Another FDA 
interviewee noted that as part of their training new medical reviewers are required to attend 
special classes, including courses that focus on critical writing and communication skills, but that 
most of the learning is still “in-service” or on-the-job training.   One division director indicated 
with satisfaction the use of an annual “West Virginia retreat” that emphasized people skill 
development, not science education.  A strong mentoring program would be most helpful, stated 
another agency individual, augmented with some formal management education.  Citing MIT-FDA-Industry White Paper    19 
   
previous efforts that resulted in “reviewers impervious to management training,” one agency 
official also pointed out that care is needed to ensure that new recruits are not so far along in 
their careers to be unable to change their working attitudes and habits – particularly if they are 
physicians.       
  Differences between industry and FDA officials’ perceptions also emerged in response to 
a related question assessing the quality of FDA reviewers.  While the average industry response 
was in between “fair” and “good”, the FDA average rating was significantly higher, between 
“good” and “excellent”.  
  However, when asked to evaluate the FDA leadership (team leader, deputy division 
director, and division director) of medical reviewers, industry respondents ranked the leadership 
considerably higher than the medical reviewers, on average between “fair” and “good”.   Follow-
on questioning revealed that company interactions with FDA leadership one or more levels 
above the medical reviewer were generally positive.  Industry respondents explained that 
excellent medical reviewers were likely to become team leaders and move up through the FDA 
hierarchy, generating higher ratings for the leadership.   Another industry official pointed out that 
over the last five years the FDA had made significant efforts in hiring qualified senior leadership.   
As an example, the individual noted that just several years ago the FDA’s CBER office hired a 
distinguished imaging specialist, who has since been moved to CDER; no previous 
radiopharmaceutical division head had ever been a radiologist.  
  Industry interviewees expressed significant concern over the turnover rate of medical 
reviewers at the FDA (particularly in toxicology), and while unable to cite quantitative evidence, 
a number suggested that turnover at the FDA was higher than in industry for positions of equal 
responsibility.  More importantly, upon turnover of a medical reviewer, companies were often MIT-FDA-Industry White Paper    20 
   
required to revisit numerous previous decisions that had been agreed upon with the agency, 
causing unnecessary delays (although in some other cases, speeding up reviews when a very 
senior reviewer with idiosyncratic scientific views finally retired).  Several respondents 
suggested that a formal handoff procedure, involving participation by both FDA reviewers and 
sponsor, take place whenever a turnover occurs at a critical review level.  Companies also 
acknowledged, however, that in some cases turnover within their regulatory group also delayed 
drug development.
14  FDA interviewees indicated that in their view turnover at the medical 
reviewer level had been decreasing, unlike that at the more senior division director level. 
  E.  TENSIONS EXIST WITHIN COMPANIES ON STRATEGIES FOR DEALING 
WITH THE FDA 
  Pharmaceutical and biotechnology companies were asked how well they were organized 
to deal with the FDA.  While both biotech and pharmaceutical companies envisaged themselves 
as on average being “good” in this respect, biotech’s self-perceptions were slightly higher than 
those by pharmaceutical respondents.   
  Follow-on discussion revealed that an elaborate regulatory group is typically set up 
within each company, acting as the primary link between the rest of the company and the FDA.  
The majority of interviewees indicated that this structure usually works reasonably well.  
However, several interviewees noted that pressures from general management and marketing 
occasionally forced the regulatory group into confrontational situations with the FDA.  
Moreover, a substantial number acknowledged that mergers or acquisitions had made interacting 
with the FDA more difficult, in part because of inconsistent regulatory practices, and different 
histories and cultures among the new partners in how aggressive or accommodating they should 
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indicating that in their experience, mergers and acquisitions often led to loss of some of the best 
scientists, disagreements on dosing, labeling and other clinical strategies previously employed by 
the new partners, and confusion and uncertainty resulting in delayed communications with the 
FDA.  
  F.  DIVERSITY IN CONFRONTING AND DISAGREEING WITH THE FDA 
  Industry officials had bimodal responses to questions regarding whether companies were 
fearful of disagreeing with the agency on protocols; roughly equal numbers “agreed” their 
company was afraid to push back, or either “disagreed” or “strongly disagreed”.  Pharmaceutical 
company interviewees were more likely to agree that their regulatory groups were hesitant to 
confront the agency, whereas biotech companies indicated they were less fearful to push back on 
the FDA regarding clinical protocol requirements, although this difference was not quite 
statistically significant (p-value of no difference, 0.095).   
  G.  INSUFFICIENT DOSING ANALYSES IN PHASE II TRIALS COMMON  
  Bimodal responses also occurred in regards to whether companies ran additional clinical 
trials not required by but in anticipation of questions the FDA might ask.  Biotech companies 
were much less likely to run such additional trials, whereas pharmaceutical companies indicated 
they did.  Follow-on discussion revealed that in many cases companies ran additional trials for 
marketing and/or labeling purposes (including quality of life analyses).  While in a strict sense a 
few of these trials were unnecessary for the approval of the drug based on FDA requirements, 
some companies indicated they have tended to run additional Phase II trials to ensure they had 
identified the proper dose effective range, thereby reducing downside risks associated with 
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  A substantial number of company interviewees stated that failure to run a sufficient 
number of Phase II trials to detect the appropriate dose range had been instrumental in causing 
failures in Phase III.  Some acknowledged they had witnessed development programs within 
their company that progressed too rapidly through Phase II in order to get to Phase III, perhaps 
due to demands and pressures from the investment community to show progress in reaching the 
next targeted development milestone.   
  Many of the issues raised by industry were also voiced by FDA officials, particularly 
those involving rather hurried Phase II trials and insufficiently extensive dosing analyses.  
Several FDA interviewees identified the industry’s tendency to focus excessively on once daily 
dosing regimens, for in some cases that simply was unlikely to be efficacious; in one failed 
Phase III study with a once-daily dosing, for example, the half-life of the drug was only four 
hours, and the drug was cleared before exerting any significant therapeutic effect. 
  H.  VALUATIONS OF EXISTING AND ADDITIONAL COMMUNICATIONS  
    WITH THE FDA VARY SYSTEMATICALLY EXCEPT IN PHASE II 
  Companies were asked to rate the quality of their current communications with the FDA 
during the various development phases, and their valuations of additional communications.  A 
striking set of findings was the uniformly high valuation by industry and the FDA of additional 
Phase II informal communications, but systematic discordant FDA-industry valuations of such 
additional communications during the other drug development phases.  Industry and FDA 
valuations of the quality of current state of communications was generally higher during the later 
development phases than in earlier stages.  
   Biotech companies on average rated the current pre-clinical communications with the 
FDA as being “good”, but pharmaceutical companies rated their pre-clinical communications MIT-FDA-Industry White Paper    23 
   
significantly lower, slightly less than “fair”.  A similar pattern of responses emerged for quality 
of communications during Phase I.   However, FDA interviewees consistently rated the quality 
of their communications with industry sponsors during the pre-clinical and Phase I stages more 
favorably than did industry.     
  The assessments of quality of current communications between sponsors and the FDA 
were much more uniform for Phase II, but this uniform rating was not a stellar one.  Both biotech 
and pharmaceutical companies rated the quality of their current interactions during Phase II as 
being on average between fair and good, as did the FDA.  A consistent theme in cases where 
industry rated communications as “fair” was the perceived variability in communications, 
ranging from extremely poor to excellent, across the FDA’s therapeutic divisions.  Follow-on 
discussion with FDA interviewees suggested that the FDA was aware of this variability in 
communications quality with industry across the FDA’s divisions during the early development 
phases.   One FDA official noted that the FDA had relatively little experience in the discovery 
stage, although it has about 250 pre-IND meetings annually with sponsors.   
  Viewed from both industry and FDA perspectives, the quality of current communications 
between industry and the FDA was generally higher during the later development phases than in 
earlier stages.   During Phase III, both the FDA and overall industry rated the quality of these 
communications as being close to “good”; similarly,  FDA and overall industry  perceptions 
were that the quality of communications during the NDA/BLA review stage was “good”.  . 
  To examine the importance of milestone meetings with the FDA, companies were asked 
to rate the value of the consultation at the end of Phase II, prior to Phase III.  At this meeting 
decisions are often made on scoping out final details for the design of and endpoints used in the MIT-FDA-Industry White Paper    24 
   
pivotal Phase III trials.  Biotech and pharmaceutical respondents uniformly rated this 
consultation as being on average close to “very valuable”.    
  Notably, while both pharmaceutical and biotech companies find the end of Phase II 
meeting to be very valuable, earlier we reported they also rate the quality of current interactions 
during Phase II as only on average being “fair”.  Follow-on discussion suggested that industry 
believed that significant opportunities exist for higher quality communications during this key 
drug development phase.  Some industry interviewees suggested that instituting a user fee 
program analogous to PDUFA for early clinical studies might be useful, although perhaps not all 
the way back to the IND or Phase I stages, particularly since a considerable number of INDs are 
filed by individuals and/or non-profit organizations.    
  Company and FDA interviewees were asked how valuable additional informal 
communications would be in the various phases of drug development.  With little variability 
among them, companies rated such communications extremely highly -- being between 
“valuable” and “very valuable” during the pre-clinical and all the clinical phases, as well as 
during the NDA/BLA review process.  One global head of R&D summarized industry’s view 
succinctly, saying “Communication leads to increased collaboration, and increased collaboration 
leads to successful drug development.”   
  By comparison, in four of the five stages, FDA interviewees rated the value of such 
additional informal communications with sponsors as significantly lower than did industry – pre-
clinical, Phase I, Phase III and NDA/BLA review.   In each of these four stages, while industry 
valued additional informal communications with the FDA as being on average between 
“valuable” and “very valuable”, mean FDA valuations were either “ambivalent” or in between 
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  However, a striking result is that only during Phase II do industry’s and the FDA’s 
valuations of increased informal communications match each other – both rating these between 
“valuable” and “very valuable”.   Notably, FDA interviewees apparently believe that the value of 
additional informal communications is much higher in Phase II than during other drug 
development stages.   Follow-on discussion with FDA interviewees revealed their belief that 
Phase II dosing issues were critical, and that a more formalized and extensive Phase IIA meeting, 
scheduled at the time the first data on dosing become available, would be very useful.   
  The FDA’s experience is that at this stage of the drug development process, there is 
frequently a tension between the sponsor’s “academic science” and “commercial interests”, and 
that a more formalized discussion and review of initial pharmacokinetic and dosing data could 
help to clarify development issues.   At that meeting, FDA officials envisaged an increasingly 
important role for clinical pharmacological analyses.  Waiting until the end of the Phase II 
studies was often too late, they argued, for by then sponsors had often made up their minds on 
dosing ranges for the subsequent Phase III pivotal studies.   Another FDA interviewee noted that 
currently a Phase IIA guidance paper was being drafted and discussed with industry, which it 
was hoped would help sponsors deal more preemptively with dosing issues. 
  Our survey indicated further that industry was willing to put its money where its mouth 
is.  Specifically, to assess the strength of their desire for increased communications, industry 
interviewees were asked whether their companies would be willing to pay more for 
communication with the FDA during various development phases to help the FDA strengthen 
and expedite clinical development reviews, and to facilitate discussions on various regulatory 
issues by hiring additional staff.    For Phase I, 70% of respondents indicated they would be 
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willing to pay between $500K and $1 million.  Although 10% of respondents were unwilling to 
pay any PDUFA-type fees during Phase II, about 40% were willing to pay between $100K and 
$500K, another 40% were willing to pay between $500K and $1 million, and 10% were willing 
to pay more than $1 million.  Finally, while 30% of respondents were unwilling to pay and 
PDUFA-type fees for Phase III, 40% were willing to pay between $100K and $1 million, and 
30% were willing to pay between $1 million and $5 million.  In none of the three phases was 
there any statistically significant difference between pharmaceutical and biotech companies, 
although during Phase III pharmaceutical company willingness to pay tended to be greater than 
that by biotech firms. 
  These findings on the willingness of both biotech and pharmaceutical companies to pay 
additional user fees underscore the industry’s perceived importance of participating in additional 
quality communications with the FDA.  In some instances, however, follow-on discussion 
revealed that certain companies were hesitant to commit to paying additional user fees unless 
they could be assured any incremental funds would in fact be used to hire additional staff 
devoted to improving communications between the FDA and sponsor, and that metrics would be 
put in place to measure and monitor the incremental hiring and review efforts.  
  Although on average FDA officials valued additional informal communications in the 
early development phases less highly than did industry, several FDA interviewees believed there 
were substantial differences across companies in the likely benefits of such additional 
communications, with small and less experienced companies being most likely to benefit.   One 
interviewee stated that “Pfizer doesn’t need it”, and then added, “Merck has three people who 
have been to more FDA meetings than I have.”      
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  I.  INDUSTRY CAUTIOUS REGARDING DEVELOPMENT AND 
VALIDATION OF BIOMARKERS AND SURROGATE MARKERS 
  The FDA’s March 2004 “Critical Pathways” document argued that “The appearance of 
new quantitative measuring technologies absolutely galvanizes new drug research.”  The 
document then went on to state: “Additional biomarkers (quantitative measures of biological 
effects that provide informative links between mechanism of action and clinical effectiveness) 
and additional surrogate markers (quantitative measures that can predict effectiveness) are 
needed to guide product development.”
15   
  While industry interviewees exhibited some enthusiasm for increased use and 
development of surrogate markers, we learned that their outlook was tempered with considerable 
caution.  A substantial number indicated that without appropriate guidance from the FDA, use of 
new surrogate markers for primary efficacy endpoints was simply too risky an undertaking. 
  Industry interviewees had a bimodal response to whether their company would be willing 
to use surrogate markers under current FDA guidelines, with 50% indicating they were 
“somewhat likely” or “very likely” vs. 50% being “ambivalent”, “not likely” or “very unlikely”.  
In cases where interviewees indicated they were “very likely” to use a surrogate marker, they 
typically also stated that they were attempting to validate the surrogate marker simultaneously 
with their ongoing clinical trials, or were employing a marker previously “accepted” by the FDA 
(e.g., CD4+ T-cell counts for AIDS). 
  Given the challenges in validating surrogate markers, we then inquired whether economic 
incentives, such as that from patent protection, would induce companies to engage in additional 
development and validation of surrogate markers.  While the average response was essentially 
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differences by interviewee rank; the more senior management (executive vice presidents and 
higher) believed their company would be less likely to employ surrogate markers if patent 
protection were available, whereas those with rank of vice-president or lower stated their 
company would be more likely to do so.   Interestingly, while CRO interviewee responses 
(which we classified separately from industry and FDA) were generally indistinguishable from 
those of industry on most issues, each of the (admittedly small number of) CRO interviewees 
indicated they would be “very likely” to employ and validate surrogate markers were patent 
opportunities available.    
  Follow-on discussion diverged widely.  Several interviewees in both pharmaceutical and 
biotech companies stated that it would not be in the interests of the research community, public 
health or even in the long-term interest of their company if surrogate markers could be patented, 
for that could impede use of critical research tools in their subsequent drug development efforts.  
Rather than patenting the marker, a number of interviewees suggested an extension of market 
exclusivity (such as that granted for pediatric indications), in exchange for placing the biomarker 
in the public domain, freely available for use by other researchers and developers. 
  Additional discussion indicated great hesitancy on the part of interviewees to rely on 
surrogate markers given current FDA guidelines and practices.  While numerous interviewees 
indicated that biomarkers were extensively and increasingly used within their company to 
evaluate safety concerns or to assist in “go/no go” decisions, in most development programs 
traditional and already-accepted clinical endpoints still trumped biomarkers as efficacy and 
safety endpoints.     
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J.  DISAGREEMENT ON THE VALUE OF FDA ADVISORY BOARD PANEL 
MEETINGS 
  FDA division directors appoint advisory board members in different therapeutic areas to 
assist them in decision-making.  The most public context in which advisory panels provide 
advice to the FDA is in the final stages of the NDA/BLA review process, after the FDA has had 
time to review and assess data from the application.  Advisory board panel meetings are public 
and typically webcast.  In most cases the sponsor initially makes a presentation, next the FDA 
summarizes its analyses, patients’ advocacy groups make testimonials, advisory board panel 
members ask questions and finally, the advisory board panel votes on whether to recommend to 
the FDA that the application be approved.  In most but not all cases, the FDA agrees with the 
panel’s recommendations.   Notably, while the FDA advisory board panels are not involved in 
the clinical development component of drug development, they do in fact play a key role in the 
drug approval process. 
  Industry is sharply divided in its valuation of this advisory process and panel meeting.  
On average, industry was “ambivalent” in its evaluation, with there being no systematic 
differences among pharmaceutical and biotech respondents.  However, interviewees at the FDA 
rated this process much more favorably, on average in between “valuable” and “very valuable”.   
CROs tended to agree more with the FDA than with industry on this issue.   
  Proponents of the advisory panel process indicated that it was a critical point in the 
NDA/BLA process that allowed the public and practitioner physicians to evaluate the drug, as 
well as witness the FDA at work.  Detractors were critical of the advisory board process in no 
uncertain terms.  Several interviewees likened the process with colorful descriptors as such 
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interviewees expressed great concern over the confrontational nature of the hearings.  According 
to several companies that have had very successful approval hearings, yet are sharply critical of 
the process, the meeting is set up with the sponsoring company on one side, the FDA on the 
opposite side, and the advisory board as the adjudicator.  Some interviewees noted that in 
communications with FDA officials prior to the panel meeting, the FDA voiced generally 
favorable evaluations, yet at the public hearing the FDA voiced primarily antagonistic views. 
  Industry interviewees indicated that substantial amounts of money and time are spent 
preparing for the “show.”   One company said that in preparation for this meeting, it prepared 
1000 backup slides, while another claimed the number to be 1200.  These meeting preparations 
are highly labor-intensive.  While agreeing that the public is entitled to learn about the 
NDA/BLA details given current Federal regulations (although also acknowledging that what is 
publicly disclosed at a meeting attended by competitors raises strategic issues for sponsors), and 
that it is important the public see the FDA at work, industry officials often argued that the current 
process does not do proper service to the sponsor or the FDA.   
  Several interviewees, who previously were high-level FDA personnel prior to joining 
industry, stated that panel experts are often poorly prepared for the review, “reading the material 
on the plane ride to the FDA.”  These respondents argued that given that the review process takes 
many FDA personnel several months, it is improbable that a panelist could gain sufficient 
understanding to render an appropriately informed decision after only a few hours of review 
time.   
  A substantial portion of industry respondents voiced concern over the qualifications of 
advisory panel members, indicating that more qualified experts were often excluded due to 
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stated that the panel meeting environment brought out some of the worst type of behavior by 
academic panel members, enabling them to “toot their horn and spout off useless remarks.”   
  From the perspective of several industry respondents, the FDA was eminently well-
qualified to make the decision on whether to approve the NDA/BLA, following its typically 
extensive and thorough review of all the safety and efficacy data, and that advisory board panel 
meetings were unnecessary.  When controversial issues emerge, they argued, a better way of 
managing disagreements or uncertainties would be to have another government agency such as 
the NIH convene a forum attended by leading experts (even those with company affiliations), the 
FDA, industry, and academic personnel.   It was not uncommon for these types of discussions to 
move to the more general qualitative issues of how dispute resolution could be better handled at 
the FDA.  Later on we comment on this issue further. 
  While on average FDA interviewees viewed the advisory board panel process more 
favorably than industry, agency officials were aware of problems, and had some suggestions for 
improvement.  First, for the meetings to be constructive, considerable work was required by 
FDA staff, a staff already stressed by what one official called a “Meetings R Us” mentality, with 
more than 1300 meetings annually between divisions and sponsors.  Another FDA interviewee 
opined that the advisory board panel meetings are sometimes helpful, sometimes not, and then 
argued that decisions regarding approval often are more nuanced that just simply involving 
safety and efficacy.  In particular, approval decisions often concern detailed regulatory issues 
such as labeling considerations, for which panel members typically have little experience or 
training.  These issues should be addressable, but considerable care must be given in choosing 
panel board members, for their clinical experience provides a valuable perspective in assessing 
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all depends on how well you select your participants.”  Yet another agency official suggested 
using advisory board panels only for selected applications, where their input is clearly needed. 
  Finally, a common theme that emerged from follow-on discussions with industry was that 
these advisory board panel meetings provided the FDA and industry a unique opportunity to 
educate the public (and the FDA staff) on the importance of risk management in the drug 
regulatory process – not just the safety and toxicity risks from using the new drug, but also the 
risks to patients if access to this new medicine is denied or delayed.  Up to now, industry and 
senior FDA staff have not seized the opportunity to demonstrate at these public forums the utility 
of the concept of employing “reasonable risk” as an approval criterion.  Rather, the public has 
been led to believe that drugs can and should be “absolutely safe,” which industry believes is in 
practice impossible.  While in principle the advisory board panel meeting process could provide 
such public education, industry and the FDA have not yet worked sufficiently hard to attain that 
goal.   
V.  DISCUSSION AND DE NOVO “THINKING OUTSIDE THE BOX” 
  The initial portion of the interviews we conducted involved interviewees responding to 
our written statements or questions on a scale of one to five, and indicating to us which of the 
issues raised were of sufficient importance or complexity that they wanted us to come back to 
them later on in the interview.  Near the end of each interview with both industry and FDA 
respondents, we posed the following question orally:  “If you had the opportunity to create the 
FDA de novo, on what would you focus your efforts, and five years from now, in what ways 
would you hope the FDA would differ most markedly from what it is today?”  As a practical 
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and expanding on early questions, and on opining on the de novo hypothetical.   Our summary 
also mixes them.   
  Although respondents’ comments ranged widely, three sets of issues were raised 
repeatedly, in some cases both by industry and the FDA.  First, industry accepts the notion that 
the onus of developing new medicines is on them, and not on the FDA.  They accept that the 
missions of the FDA are to ensure the safety and efficacy of new medicines, and to advance the 
public health by “helping to speed innovations that make medicines and foods more effective, 
safer and more affordable.”   The missions and tasks facing the FDA differ from those facing 
industry.  A strength of the FDA to this point is that its mandate has been perceived by industry, 
the FDA and the public as being limited to evaluating medications based on scientific criteria 
involving safety and efficacy, and in particular, not on economic criteria involving comparative 
costs and benefits.  Industry is concerned that with closer collaborations between the FDA and 
the Centers for Medicare and Medicaid Services, this valuable separation of mandates might 
become blurred, as it has already in member states of the EMEA.  This blurring is likely to 
expand as the Medicare Part D prescription drug benefit is implemented in 2006. 
  Second, industry and much of the current FDA senior leadership believes that over the 
years, the FDA has focused disproportionate attention on the first of the two missions (product 
safety and efficacy), at the expense of meeting the second mission (helping speed innovation), 
although when we conducted our interviews (in Spring 2004, prior to the voluntary withdrawal 
of Vioxx), industry believed it was observing some welcome signs of change.  With respect to 
“helping to speed innovations,” guidance from and collaboration with the FDA can have 
significant positive impacts on how quickly and successfully pharmaceutical and biotech firms 
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there is much room for closer collaboration between industry and the FDA that promotes the 
public health, particularly by sharing information during early development stages in which the 
FDA’s valuable knowledge involving classes of compounds and molecule structures could help 
industry avoid failures and needlessly placing patients at risk.   
  Third, a persistent theme we heard from industry interviews (and to some extent, also 
from the FDA) was that communications processes with the FDA needed to be better managed.  
Increased communication and interactions with the FDA were viewed by industry as 
substantially increasing information transparency and reducing information asymmetry between 
the FDA and sponsors, thereby mitigating development uncertainty and risk, making the 
inherently risk drug development process more predictable.   To be effective, however, these 
increased communications efforts must be coupled with standard performance metrics and best 
practices across the FDA’s therapeutic divisions.   Currently industry believes there is enormous 
variability across the FDA’s 17 therapeutic divisions and areas in the quality of communications 
between the FDA and industry. 
  Both industry and FDA respondents recognized the existence of an inherent tension, 
however, between credibly regulating an industry and working with it to facilitate development 
of innovative products, i.e., between gate-keeping and development.  FDA officials expressed 
particular strong caution that their supportive role be confined to collaboration, and not include 
extensive partnering.    A delicate balance must be maintained between attempting to 
accommodate industry’s desires to know and the agency’s need to safeguard its decision-making 
process.  That being said, both industry and the FDA recognize that later phase information 
communications are by necessity likely to be more constrained than those possible at earlier 
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informal communications voiced both by FDA and industry may signal that such efforts will be 
forthcoming.  However, the discordant FDA-industry valuations of such additional 
communications during the earlier drug development phases are notable.  Both industry and FDA 
officials stated that these issues merit careful consideration as the FDA carries out its “Critical 
Pathways” initiatives with industry, academia, other government agencies, and the public. 
  Finally, our “de novo” questions also yielded several less commonly voiced opinions.  
Among these were the following: 
·  Redefine the medical reviewer position at the FDA and mix it in with service at 
the NIH and CDC.  Make the job description more attractive, and perhaps 
institute a fellowship program. 
·  Involve the medical associations more in the review process, particularly during 
the advisory board panel meeting. 
·  Have one toxicology unit serve all therapeutic divisions.  More generally, the 
various therapeutic divisions are aligned too separately as silos, and instead there 
needs to be more cross-division consultation.   
·  Make the FDA more distant from the political process.  The Commissioner of the 
FDA should be just as independent of the executive and legislative branches as is 
the Chairman of the Board of Governors of the Federal Reserve. 
·  Split regulatory supervision of food and agriculture off from the FDA, making it 
focused only on the safety and efficacy of medicines.   Asking senior staff to be 
conversant with such wide-ranging issues involving food and drugs is practically 
unreasonable.   
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VI.  RECOMMENDATIONS:  THEMES FROM QUALITATIVE DISCUSSIONS  
  The less structured qualitative portions of our confidential interviews with 49 industry 
and eight senior FDA officials repeatedly focused on a number of suggested policy 
recommendations, which interviewees believed could lead to improved regulatory interactions 
between industry and the FDA and make the drug development and regulatory process more 
efficient, without compromising patient safety and welfare.  Among those voiced most 
frequently and with the greatest intensity wee the following:  
·  Institute metrics and goals analogous to those present in the Prescription Drug User Fee 
Acts of 1992, 1997 and 2002 into the drug development portion of interactions with the 
agency.  Sponsor companies would be charged reasonable levels of user fees for 
increased interactions during Phases II and III, not just upon submitting for review 
approval a New Drug Application or a Biologic License Application.  The funds from 
sponsors would be used to hire additional, well qualified FDA staff to increase the 
interactions and information flows with sponsors.  
·  Contract with an independent consultant to identify divisions that are managed well, and 
that have been successful in fulfilling both portions of the FDA mission statement.  
Implement and regularly monitor the diffusion of standard best practices from the top-
performing divisions across the entire set of agency divisions.   Report on progress of the 
diffusion of best practices across therapeutic areas in the PDUFA annual report. 
·  Establish an oversight board consisting of industry, agency officials, and premier external 
scientists (possibly at NIH or CDC), that convenes at a minimum once a year to evaluate 
retrospectively the development and regulatory history of a randomly selected number of 
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group would provide feedback to the FDA and industry and present actionable 
recommendations to improve the regulatory and development process. 
·  Establish an exchange program involving industry and FDA scientists that exposes 
industry to the FDA and vice-versa.  To mitigate subsequent potential conflicts of 
interest, the FDA scientists would need to function in an industry project outside the 
review domain of the division employing them at the FDA. 
·  Collaborate on creating a more structured and effective dispute resolution system.  The 
current ombudsman system is rarely, if ever used, and informal processes are 
inconsistent, creating unnecessary uncertainty and delaying decision-making. 
·  Establish a knowledge data base, using modern information technology, that stores and 
makes available information on issues concerning classes of compounds and molecule 
structures.  Because the FDA is de facto the custodian of a knowledge base encompassing 
a much wider range of molecules and safety issues than is known by any in industry, it 
has a unique opportunity to provide developers with important information concerning 
safety and efficacy.  These data could also be used in simulations and modeling involving 
safety and toxicity issues, projected both backwards and forwards.  Certain proprietary 
and intellectual property issues will need to be addressed to facilitate the sharing of such 
information.  However, allowing companies in ignorance to conduct clinical trials with 
compounds that share similar important properties with compounds that have previous 
safety or toxicity failures is inconsistent with protecting the public health. 
Finally, we believe it important to bear in mind that issues involving interactions between the 
FDA and industry – the focus of this research – constitute only a portion of the much larger 
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commensurate growth in the number of NDAs/BLAs submitted for approval to the FDA.  While 
resolution of the communication and management issues between the FDA and industry would 
improve substantially the drug development process and make it more efficient, these process 
solutions are not a substitute for the underlying discovery and development of innovative 
therapeutics.  Ultimately, both industry and the FDA believe the onus of drug development rests 
with the pharmaceutical and biotechnology industries.  The complementary missions of the FDA 
are to continue to ensure the safety and efficacy of medicines, and simultaneously to advance the 
public health by helping to speed innovations that make medicines accessible to the patients who 
need them. 
VII.  STUDY LIMITATIONS 
  Our study has a number of limitations.  Although the study team took considerable care 
in developing and testing the quantitative and qualitative questionnaires, in retrospect it is clear 
the questions could have been enhanced to delve deeper into some of the key issues that 
emerged.  More pointed questions would have been extremely valuable in elucidating 
distinctions when the interviewee responded by giving a weighted average response.  For 
example, interviewees often responded with the answer “fair” or “variable” to the questions 
regarding medical reviewers.  Refinement of these questions to solicit feedback on a per division 
basis or with percentage estimates might have been more useful. 
  The sample of companies interviewed during this research was not chosen at random 
from a listing of biotech, pharmaceutical, and CRO companies.  It was important for the purpose 
of the research to interview personnel at companies that had considerable experience with the 
FDA and drug development.  The companies we chose to interview were admittedly non-
random, and quite successful – as of April 2004, they had a total market capitalization of more MIT-FDA-Industry White Paper    39 
   
than one trillion dollars.  A random sampling of companies engaged in drug development would 
not have ensured coverage of companies with significant development experience.  While not 
proven, we believe that the sample is representative of the major stakeholders of drug 
development within industry.   
  Virtually all the industry interviewees were engaged in R&D or regulatory activities.  
General management and senior executives (e.g. chief executive officer, chief financial officer) 
were not interviewed.  Their opinions on interactions with and evaluations of the FDA might be 
very different given the greater pressure they face from the investment community and 
shareholders. 
  Similarly, the eight senior FDA officials interviewed may not be representative of the 
entire leadership at the FDA.  While the names of several of the FDA interviewees were 
provided by the study team, the majority of the eight FDA interviewees were selected by the 
FDA.  
  Finally, these interviews were conducted in Spring 2004, several months before Merck’s 
voluntary withdrawal of Vioxx on September 30, 2004, and also before Congressional hearings 
on the safety of antidepressant medications for pediatric populations.  The opinions and views of 
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